Tag: biopharma

Institute of Chemical Technology (ICT), Mumbai, is conducting the 3rd Biosimilar Workshop from February 3-8, 2020. Participants will also have the opportunity to hear from leaders of the Indian and global biopharma industry, providing a perspective on the training programs...............

Early combination treatment strategy with vildagliptin and metformin was superior to the standard of care in newly diagnosed type 2 diabetes patients. The landmark VERIFY study is the first to investigate the long-term clinical benefits of this early combination strategy in type 2 diabetes...................

Sun Pharma and China Medical System Holdings have entered into licensing agreement for generic products in Mainland China..............

Sun Pharma gets an exclusive global license for CSIR-IICT’s patents related to certain compounds with potential therapeutic activity across multiple indications. CSIR-IICT to get upfront plus milestone payments and royalties on net sales...................

A batch of certificate course on computational approaches to drug design and development has just been completed at the institute as a part of its skilling initiative.....................

Combined portfolio enables Agilent to provide a more complete and integrated solution for customers in the important and fast-growing area of live cell analysis. BioTek is a recognized leader for plate-readers and imaging systems with complementary offerings to Agilent’s portfolio...........................

Total Agilent Experience has fast become the place to be for professionals from chemical, food and pharma industries over the years, drawing over 300 scientists and researchers from across the country....................

Dr Manoj Kumar Bhat has taken over as the new director of the National Centre for Cell Sciences, an autonomous institute located within the academically-enriched campus of the Pune University. The institute is aided by the Department of Biotechnology, Government of India....................

Potapov’s appointment follows Takeda’s recent acquisition of Shire Pharmaceuticals – enabling Takeda to become a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan...............

As per the study by IQVIA Institute for Human Data Science, while the likelihood that a drug entering clinical development would be a success was 11 percent, down from 14 percent in 2017, eight identified trends could increase R&D productivity by double digits during next five years.................